PACIFIC-PRESERVED : PhenomApping, ClassIFication, and Innovation for Cardiac Dysfunction - HF With PRESERVED LVEF Study

Inclusion Criteria: All subjects * Affiliation to a social security scheme, universal medical coverage (CMU) or any equivalent scheme * Physical state compatible with the carrying out of the investigations according to the judgment of the investigator * Procedure for obtaining consent For HFpEF patients: * Hospitalization in one of the partner hospitals in the last 30 months * With a diagnosis of symptomatic congestive heart failure (NYHA II to IV) * With a plasma concentration of BNP ≥ 100 μg / ml or NT-proBNP ≥ 300 μg / ml or having had an administration of a dose of intravenous diuretics during hospitalization for congestive heart failure * Left ventricular ejection fraction ≥ 50% * Hospital discharge for at least 2 months For HFrEF patients: * Hospitalization in one of the partner hospitals in the last 30 months * With a diagnosis of symptomatic congestive heart failure (NYHA II to IV) * Plasma concentration of BNP ≥ 100 μg / ml or NT-proBNP ≥ 300 μg / ml or administered a dose of intravenous diuretics during hospitalization for congestive heart failure * Hospital discharge for at least 2 months * Left ventricular ejection fraction ≤ 40% * Matched age and sex to HFpEF patients (for participants to extensive phenotyping) For subjects apparently without heart failure : * Subject without a notable medical history or medical history within the last 5 years * Normotensive or who may have an essential hypertension of grade 1 (≤159 / 99 mmHg), treated or not * Can present a dyslipidemia, treated by hygieno-dietetic measures alone * Sinus heart rate * Estimated glomerular filtration rate ≥ 60 ml / min (CKD epi) * Matched age and sex to HFpEF patients (for participants to extensive phenotyping) Exclusion Criteria: All subjects * Pregnancy or breastfeeding * Participation in another interventional study * Person placed under the safeguard of justice * Subject that can not understand the procedures related to the protocol * Severe obesity (BMI \> 40 Kg / m2) * For those performing the injected MRI: Patient who has already had a severe allergy to gadolinium MRI contrast agents * For those performing the injected MRI: MRI usual contraindications: Pace-maker, defibrillator, metallic objects * Administration of a vaccine dose (including anti-Sars-Cov-2) less than 3 weeks old For both HFpEF and HFrEF patients: * History of right ventricular infarction * History of cardiac transplantation or circulatory assistance * Major surgery scheduled for less than 6 months, coronary revascularization of less than 3 months * Pacemaker or any implanted device (or foreign body) not compatible with MRI * Presence of very severe co-morbidity: end-stage renal failure (GFR \<15ml / min), severe chronic obstructive pulmonary disease (COPD), severe valve disease (including severe aortic stenosis), organ transplantation * Hypertrophic cardiomyopathy of known genetic cause * Hereditary amyloidosis with disabling neuropathy * Amyloidosis under specific treatment * Other antecedent of known congenital heart disease type, Post-embolic chronic pulmonary heart, Restrictive Cardiopathy, Diagnosed Fabry Disease For HFpEF patients: \- History of systolic dysfunction with proven LVEF reduction (≤ 40%) For subjects apparently without heart failure : * Medication use other than pure systemic or local estrogen / progestin and progestin contraceptives and paracetamol, at the discretion of the investigator * Acute pathology within 8 days prior to inclusion * Cardiac or vascular organic impairment or apparent chronic diseases * Chronic treatment outside a treatment for high blood pressure * Having already had ≥3 MRI with injection of gadolinium contrast agents